ImmunityBio Inc Aktie News

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), ein Immunotherapie-Unternehmen in der kommerziellen Phase, gab heute bekannt, dass Dr. Jim Yong Kim dem Unternehmen als Vice Chairman beigetreten ist. Dr. Kim wird in einem neu geschaffenen Office of the Executive Chairman tätig sein, wo er sich auf die Stärkung der internationalen und globalen Beziehungen des Unternehmens ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), ein Unternehmen der Biotechnologie im kommerziellen Stadium, gab heute die finanziellen und operativen Ergebnisse für das zweite Quartal zum 30. Juni 2026 bekannt. Die Nettoerlöse aus Produktverkäufen beliefen sich auf $50,7 Millionen, was einem Wachstum von 92 % gegenüber dem Vorjahr und einem sequenziellen Anstieg von 15 ...

CULVER CITY, Kalif. -- (BUSINESS WIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), ein vertikal integriertes Biotechnologieunternehmen in der kommerziellen Phase, gab heute bekannt, dass das Emirates Drug Establishment (EDE) der Vereinigten Arabischen Emirate (VAE) eine Marketingzulassung für ANKTIVA® (nogapendekin alfa inbakicept) für zwei Indikationen erteilt hat. Die Zulassung umfasst ANKTIVA 0,4 m...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirec...

NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Sci...

NEW YORK, May 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityB...

IBRX Investors with Losses Encouraged to Contact the Firm BeforeMay 26th Deadline SAN FRANCISCO, May 23, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter...